Tarsus Pharmaceuticals, Inc.
TARS
株式のランク
#4650
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
株価
$70.00
時価総額
$3.28B
変化（1日）
2.84%
変化（1年）
-4.02%
国
US
取引 Tarsus Pharmaceuticals, Inc. (TARS)
カテゴリー
Healthcare
Tarsus Pharmaceuticals, Inc.（TARS）のEPS
June 2026 時点のEPS TTM: $-1.09
Tarsus Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-1.09です。2023年末には、EPSは$-4.62で、2022年のEPS$-2.52と増加でした。
Tarsus Pharmaceuticals, Inc.のEPS履歴（2018から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
